Tango Therapeutics (TNGX) Share-based Compensation (2020 - 2026)
Tango Therapeutics (TNGX) posted quarterly Share-based Compensation of $77.1 million for Q1 2026, up 962.72% year-over-year from $7.3 million in Q1 2025, and up 1189.3% quarter-over-quarter from $6.0 million in Q4 2025.
Tango Therapeutics (TNGX) Share-based Compensation (2020 - 2026) Analysis & Trends
Tango Therapeutics' Share-based Compensation history runs 7 years deep, the most recent figure standing at $77.1 million for Q1 2026.
- In Q1 2026, Share-based Compensation rose 962.72% year-over-year to $77.1 million; the TTM figure through Mar 2026 stood at $77.1 million (up 161.95% YoY), while the FY2025 annual figure was $26.4 million, down 8.54% from the prior year.
- Share-based Compensation for Q1 2026 stood at $77.1 million, up from $6.0 million in the prior quarter.
- The five-year high for Share-based Compensation was $77.1 million in Q1 2026, with the low at $3.2 million in Q1 2022.
- The 5-year median for Share-based Compensation is $6.0 million (2025), against an average of $9.7 million.
- The sharpest annual moves came in 2022 and 2025: Share-based Compensation soared 160150.0% in 2022, then decreased 19.86% in 2025.
- Tango Therapeutics' Share-based Compensation stood at $3.8 million in 2022, then grew by 28.9% to $4.9 million in 2023, then soared by 52.94% to $7.5 million in 2024, then fell by 19.86% to $6.0 million in 2025, then jumped by 1189.3% to $77.1 million in 2026.
- Business Quant data shows TNGX's Share-based Compensation at $77.1 million in Q1 2026, $6.0 million in Q4 2025, and $6.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Tango Therapeutics | 4.32 Bn | 3.30 Bn | - | 16.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.89 Mn |
| Jun 30, 2026 | 16.89 Mn |
| Mar 31, 2026 | 77.10 Mn |
| Mar 31, 2026 | 77.10 Mn |
| Dec 31, 2025 | 5.98 Mn |
| Dec 31, 2025 | 5.98 Mn |
| Sep 30, 2025 | 6.63 Mn |
| Sep 30, 2025 | 6.63 Mn |
| Jun 30, 2025 | 6.57 Mn |
| Jun 30, 2025 | 6.57 Mn |
| Mar 31, 2025 | 7.26 Mn |
| Mar 31, 2025 | 7.26 Mn |
| Dec 31, 2024 | 7.46 Mn |
| Dec 31, 2024 | 7.46 Mn |
| Sep 30, 2024 | 7.18 Mn |
| Sep 30, 2024 | 7.18 Mn |
| Jun 30, 2024 | 7.54 Mn |
| Jun 30, 2024 | 7.54 Mn |
| Mar 31, 2024 | 6.72 Mn |
| Mar 31, 2024 | 6.72 Mn |